Please login to the form below

Not currently logged in
Email:
Password:

Draft NICE guidance rejects Tyverb for NHS

Draft NICE guidance has recommended against the use of GSK's breast cancer drug, Tyverb, outside clinical trials

The National Institute for Health and Clinical Excellence (NICE) has released draft guidance which recommends against the use of GlaxoSmithKline's (GSK) breast cancer drug, Tyverb (lapatinib), outside clinical trials.

After consultations with pharmaceutical companies, healthcare professionals, charities and patients groups, the organisation came to the conclusion that the drug was not cost-effective when compared with current alternative treatments.

Lapatinib was developed to be taken in combination with capecitabine (Xeloda) manufactured by Genentech, for women with advanced or metastatic HER2-positive breast cancer.

"We are disappointed not to be able to recommend lapatinib," said Sir Andrew Dillon, NICE chief executive, "but evidence suggests it only extends life by a small amount of time - around 10 weeks (2.4 months) - and costs thousands of pounds more than one of the more commonly used NHS treatments for this indication - capecitabine on its own."

The committee who came to the draft guidance decision took into consideration GSK's proposed patient access scheme which would see the company pay for the cost of the drug for the first 12 weeks of a patient's treatment.

The guidance is still not final however, with a group of consultees able to appeal the recommendation following further appraisal. The appeal has a deadline of June 24, 2010.

Simon Jose, general manager, GSK UK said: "GSK has worked really hard to offer the best possible value to the NHS, which makes this decision particularly disappointing. It again highlights the limitations of the NICE appraisal process when evaluating cancer treatments for patients facing a relatively short life expectancy."

The Department of Health's (DH) response to the guidance also discussed NICE's role under the new coalition government: "We respect the expert independence of NICE, and believe that it must be allowed to continue to issue guidance free from political interference. However, we believe that there are fundamental failings within the wider system for drug pricing and access.

"There will be significant reforms to the way in which we pay for drugs so that we can give effect to our intention that patients can access the drugs most clinically effective for them; and that the price paid by the NHS reflects value for money."

10th June 2010

From: Healthcare

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...
Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...

Infographics